Business Context and Reporting Period
This Form 8-K is a current report filed by Adial Pharmaceuticals, Inc. on April 7, 2026. The filing discloses corporate governance actions taken by the Compensation Committee of the Board of Directors regarding executive and director compensation.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on equity compensation grants and does not contain financial performance data.
Material Changes
The primary material event reported is the approval of equity awards on April 7, 2026:
- Cary Claiborne (CEO & Director): Granted 37,985 Restricted Stock Awards (RSAs). 28,800 were for his role as CEO and 9,185 for his role as a Director.
- Vinay Shah (CFO): Granted 17,325 RSAs for his role as CFO.
- Tony Goodman (COO & Director): Granted 26,510 RSAs. 17,325 were for his role as COO and 9,185 for his role as a Director.
- Kevin Schuyler & Robertson H. Gilliland (Directors): Each granted 9,185 RSAs.
- Kermit Anderson (Director): Granted options to purchase 9,185 shares at an exercise price of $1.64 per share.
Guidance, Outlook, and Terms
Vesting Terms: The RSAs vest in full on the earlier of (i) the one-year anniversary of the grant date or (ii) the occurrence of a Change of Control as defined in the Company's 2017 Equity Incentive Plan.
Management Commentary: The Board approved a form of Restricted Stock Award Agreement (Exhibit 10.1) to be used for these grants under the 2017 Plan.
Risks and Contingencies: The filing does not disclose specific new risks or contingencies beyond the standard vesting conditions tied to a Change of Control.
Investor Verification Checklist
- Verify the total number of shares authorized under the 2017 Equity Incentive Plan to assess remaining capacity for future grants.
- Review the "Change of Control" definition in the 2017 Plan to understand acceleration triggers for the granted RSAs.
- Confirm the current market price of ADIL stock relative to the $1.64 exercise price for Kermit Anderson's options.
- Check subsequent filings for any amendments to the Restricted Stock Award Agreement (Exhibit 10.1).